source
- FDA delays decision on Belite Bio's Stargardt disease drug to May 12The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
- Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasisStakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…